OVERVIEW

New Drugs 2018 is organized by The Rx Consultant.

Publication Date: 03/22/2019
Expiration Date: 03/22/2022
CE Credit: 2.0 (0.20 CEU)

Course Description:
In 2018, the US Food and Drug Administration (FDA) approved 59 new drugs - the highest number in more than 10 years - including 19 first-in-class agents.

Of the 59 new approvals, 73% received priority review. This issue of The Rx Consultant focuses on the new drugs that may be important additions (including a number of “firsts”) in their therapeutic areas: influenza infection, HIV-1 infection, pneumonia and skin infections, nonmetastatic, castration-resistant prostate cancer, endometriosis, migraine prophylaxis, moderate to severe acne, and chronic, idiopathic constipation.

Goals & Objectives:
At the conclusion of this program, participants will be able to:
• List the FDA approved indication(s), state the recommended dose(s), and discuss the evidence supporting the drug’s approval and potential role(s) in therapy.
• Describe significant side effects and drug interactions.
• List the generic/brand names, dosage form(s), FDA approved indication(s), and major safety concerns.

The additional details will be posted as soon as information is available.